-$0.11 Earnings Per Share Expected for Evolent Health Inc (NYSE:EVH) This Quarter

Equities research analysts expect Evolent Health Inc (NYSE:EVH) to announce ($0.11) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Six analysts have made estimates for Evolent Health’s earnings, with estimates ranging from ($0.19) to ($0.03). Evolent Health posted earnings per share of ($0.26) in the same quarter last year, which suggests a positive year-over-year growth rate of 57.7%. The company is expected to report its next quarterly earnings results on Tuesday, August 4th.

According to Zacks, analysts expect that Evolent Health will report full year earnings of ($0.40) per share for the current financial year, with EPS estimates ranging from ($0.58) to ($0.15). For the next financial year, analysts forecast that the business will report earnings of ($0.37) per share, with EPS estimates ranging from ($1.19) to $0.04. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that follow Evolent Health.

Evolent Health (NYSE:EVH) last issued its quarterly earnings results on Thursday, May 7th. The technology company reported ($0.14) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by ($0.01). Evolent Health had a negative return on equity of 6.09% and a negative net margin of 37.17%. The business had revenue of $247.29 million during the quarter, compared to analyst estimates of $239.35 million.

Several research firms have commented on EVH. Zacks Investment Research lowered shares of Evolent Health from a “buy” rating to a “hold” rating in a report on Thursday, May 28th. Canaccord Genuity reaffirmed a “buy” rating and set a $17.00 target price on shares of Evolent Health in a report on Monday, June 1st. Goldman Sachs Group cut Evolent Health from a “buy” rating to a “neutral” rating and reduced their price target for the company from $13.00 to $8.00 in a research report on Friday, June 5th. ValuEngine lowered Evolent Health from a “buy” rating to a “hold” rating in a research report on Friday. Finally, Cantor Fitzgerald lowered shares of Evolent Health from an “overweight” rating to a “neutral” rating and cut their target price for the company from $9.00 to $8.00 in a report on Tuesday, June 2nd. Five equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $12.85.

Shares of NYSE:EVH remained flat at $$7.40 during midday trading on Friday. 1,529,700 shares of the stock were exchanged, compared to its average volume of 1,415,754. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.09 and a quick ratio of 1.09. The firm has a fifty day moving average price of $7.04 and a two-hundred day moving average price of $7.90. Evolent Health has a 1 year low of $3.50 and a 1 year high of $12.01. The firm has a market capitalization of $632.55 million, a price-to-earnings ratio of -1.87 and a beta of 1.68.

A number of large investors have recently bought and sold shares of EVH. State Street Corp raised its holdings in shares of Evolent Health by 19.6% during the first quarter. State Street Corp now owns 1,783,872 shares of the technology company’s stock valued at $9,686,000 after acquiring an additional 292,880 shares during the last quarter. Credit Suisse AG raised its stake in Evolent Health by 3.6% in the 4th quarter. Credit Suisse AG now owns 3,745,881 shares of the technology company’s stock valued at $33,900,000 after purchasing an additional 128,588 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in Evolent Health by 149.6% in the 4th quarter. Bank of New York Mellon Corp now owns 1,609,737 shares of the technology company’s stock valued at $14,569,000 after purchasing an additional 964,723 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Evolent Health by 2.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 459,908 shares of the technology company’s stock worth $4,163,000 after purchasing an additional 10,309 shares during the last quarter. Finally, Two Sigma Investments LP grew its holdings in shares of Evolent Health by 10.9% during the first quarter. Two Sigma Investments LP now owns 271,486 shares of the technology company’s stock worth $1,474,000 after buying an additional 26,744 shares in the last quarter. Institutional investors own 93.03% of the company’s stock.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates as a managed services firm that supports health systems and physician organizations in migration toward value-based care and population health management.

Featured Story: Back-End Load

Get a free copy of the Zacks research report on Evolent Health (EVH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Evolent Health (NYSE:EVH)

Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.